Sandoz’ Loryna Strategy Validated; Bayer’s Yaz Patent Struck Down A Year Before Expiration
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis is relaunching its version of the oral contraceptive after the Federal Circuit reverses a lower court and finds Bayer’s patent is invalid due to obviousness; the appeals court also finds that Biogen Idec’s Rituxan patent does not block GSK’s Arzerra.